FDA and Paradigm Health Collaborate to Accelerate Clinical Trials
The FDA has announced a collaboration with Paradigm Health to expedite clinical trial processes using an AI-powered platform. This initiative aims to streamline data collection and regulatory review by integrating electronic health records (EHRs) and transmitting critical safety and efficacy signals to pharmaceutical sponsors and the FDA. The collaboration is designed to reduce manual data entry and unnecessary data transfers, thereby accelerating the drug development process. The platform is already operational with early partners like Amgen and AstraZeneca, with trials underway at major research institutions. 
